Meeting
2023 ASCO Annual Meeting
Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.
Authors
Kelly N. Fitzgerald
Memorial Sloan Kettering Cancer Center, New York, NY
Kelly N. Fitzgerald , Ritesh R Kotecha , Andrea Knezevic , Natalie Shapnik , David H Aggen , Maria Isabel Carlo , Neil J. Shah , Martin H Voss , Darren R. Feldman , Robert J. Motzer , Chung-Han Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4545)
DOI
10.1200/JCO.2023.41.16_suppl.4545
Abstract #
4545
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.
First Author: Gennady Bratslavsky
Poster
2018 Genitourinary Cancers Symposium
Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.
First Author: Dominick Bosse
Poster
2024 ASCO Genitourinary Cancers Symposium
Comparing molecular variations and outcomes in Hispanic and non-Hispanic patients with metastatic clear cell renal cell carcinoma (ccRCC).
First Author: Sharon Choi
Poster
2022 ASCO Annual Meeting
Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of FLCN genomic alteration (GA) status.
First Author: Gennady Bratslavsky